Serodetection of Cytomegalovirus and Epstein - Barr virus Antibodies Among Hemodialysis Patients
Mohamed N. Ibrahim1
Mohamed S. Alhadi 2, 3, and Waleed Y. Elbadawy 3,1Clinical Laboratories department, College of Applied Medical Sciences, Jouf University, Qurayat, Saudi Arabia
2Biochemistry department, Faculty of Science, Ain Shams University, Egypt
3Hematology department, Wadii El-Nile Hospital, Cairo, Egypt
Corresponding Author E-mail: mnabil@ju.edu.sa
Abstract: The infection with herpesviruses as Human herpes virus-5 (cytomegalovirus-CMV) and Human herpes virus-4 (Epstein – Barr virus -EBV) is one of the main causes of morbidity and mortality in hemodialysis patients. This study aims to investigate the serostatus of CMV and EBV in patients with renal failure who underwent hemodialysis. The study included 134 cases (55 females and 79 males) with an age range of 35-68 years (mean age 37.43±13.42 years). HCMV-IgG, IgM and EBV-IgG, EBV-IgM were determined in subjects' sera. 87 of 134 (65%) were underwent hemodialysis, while 47 (35%) had normal kidney functions without HCV infection. 68 (78.2%) and 31 (35.6%) cases out 87 hemodialysis patients were positive for CMV-IgG and IgM antibodies, respectively. On the other hand, 56.3% and 20.7% of the 87 hemodialysis patients were positive for EBV-IgG and IgM antibodies, respectively. There is no significant differences were observed between females and males in terms of seroprevelance rates. The rate of positive CMV-IgG among 48-64 years hemodialysis patients was high, Whereas, EBV-IgG were detected among 39-67 years. Our data suggest that seroprevalence of CMV and EBV antibodies among hemodialysis cases is a high and cause complications for these patients.
Keywords: CMV-IgG, CMV-IgM, EBV-IgG and IgM for Hemodialysis Patients Back to TOC